Monday, Alzamend Neuro Inc. ALZN stock is trading higher after the company partnered with Massachusetts General Hospital as its contract research organization.The company has partnered to conduct a first-of-its-kind Phase 2 study of AL001 for the treatment of patients with post-traumatic stress disorder (PTSD).Lithium was the first mood stabilizer approved by the FDA and is still a first-line treatment option for bipolar disorder.Although lithium does not have an FDA-approved indication for PTSD, case repor ...